Details of the Drug Combination

General Information of Drug Combination (ID: DC95HHD)

Drug Combination Name

Eribulin Lenvatinib

Indication

Disease Entry	Status	REF
Cancer	Phase 2	[1]

Component Drugs

Eribulin DM1DX4Q

Lenvatinib DMB1IU4

Small molecular drug

2D MOL

3D MOL is unavailable

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Eribulin

Eribulin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[9]
------------------------------------------------------------------------------------

Eribulin Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[10]
------------------------------------------------------------------------------------

Indication(s) of Lenvatinib

Disease Entry	ICD 11	Status	REF
Thyroid cancer	2D10	Approved	[4]
Thyroid gland follicular carcinoma	N.A.	Approved	[5]
Thyroid gland papillary carcinoma	N.A.	Approved	[5]
Hepatocellular carcinoma	2C12.02	Phase 3	[6]
Renal cell carcinoma	2C90	Phase 3	[7]
Melanoma	2C30	Phase 2	[6]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
Ovarian cancer	2C73	Phase 1	[8]
Non-small-cell lung cancer	2C25.Y	Application submitted	[7]

Lenvatinib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[8]
------------------------------------------------------------------------------------

Lenvatinib Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Leiomyosarcoma	DC9R60D	N. A.	Phase 1	[12]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02640508) Eribulin and Lenvatinib in Advanced Solid Tumors
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6813).
3	Eribulin FDA Label
4	FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 208627.
5	Lenvatinib FDA Label
6	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
9	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
10	Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008 Sep;62(4):707-16.
11	Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.
12	ClinicalTrials.gov (NCT03526679) Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma